A PHASE 2 MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL)
Study of Experimental Product (KTE-C19) in Subjects with Relapsed or Refractory Indolent non-Hodgkin B-Cell Lymphoma
Sponsor: Kite Pharma, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR9001
U.S. Govt. ID: NCT03105336
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after a 3 day course of chemotherapy, is safe and effective in treating relapsed or refractory (r/r) indolent non-Hodgkin B-cell lymphoma (iNHL). KTE-C19 is made from white blood cells that are removed from the individual. A virus (retrovirus) is used to introduce a gene that creates a protein (called a chimeric antigen receptor or CAR) on the surface of T cells, a type of blood cell that fights infection and eliminates cancer cells. The hope is that the CAR on the T cells will bind to and kill cells that express CD19, a protein that is found on B-cell lymphomas.
This study is closed
Investigator
Ran Reshef, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with indolent non-Hodgkin B-cell lymphoma such as follicular lymphoma? Yes No
Have you received at least 2 lines of therapy for your indolent lymphoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162